Dr.Β JeddΒ Wolchok
BA, MS, PhD, MD, FASCO, FAACR, FAIO
Meyer Director, Sandra and Edward Meyer Cancer Center
corporate_fareWeill Cornell Medicine / NewYork-Presbyterian, New York
Jedd Wolchok
BA, MS, PhD, MD, FASCO, FAACR, FAIO
Dr. Jedd D. Wolchok is a physician-scientist and one of the most internationally recognised clinician-researchers in cancer immunotherapy. He is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and Professor of Medicine at Weill Cornell Medical College, where he also leads the Parker Institute for Cancer Immunotherapy Center.
Dr. Wolchok trained at Princeton University and New York University, earning his MS, PhD, and MD from NYU before completing residency and fellowship at Memorial Sloan Kettering Cancer Center, where he spent over two decades in clinical and research leadership. He played a central role in the clinical development of ipilimumab and the nivolumab-plus-ipilimumab combination, both of which transformed outcomes in advanced melanoma. In 2022, he joined Weill Cornell Medicine to lead the Meyer Cancer Center. His NIH R01-funded laboratory investigates immune resistance, tumour microenvironment biology, cancer vaccines, and novel immunotherapy strategies. With more than 30 years of post-MD experience and over 248,000 research citations, Dr. Wolchok is a member of the National Academy of Medicine and a recipient of the ASCO David Karnofsky Award.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Wolchok at Weill Cornell Medicine.
Why Consider Dr. Jedd Wolchok?
Dr. Wolchok combines landmark clinical contributions in melanoma immunotherapy with active laboratory research and senior academic leadership at one of the United States' foremost cancer centres.
Areas of Specialisation
Melanoma immunotherapy, checkpoint blockade, and translational cancer immunology
Dr. Wolchok's clinical practice is focused on melanoma, including advanced and metastatic disease. His research expertise spans the full spectrum of cancer immunotherapy, from checkpoint inhibitor biology to novel combination strategies and cancer vaccine development.
Melanoma & Metastatic Melanoma
Comprehensive multidisciplinary care for melanoma patients including immunotherapy, targeted therapy, chemotherapy, and imaging surveillance.
- arrow_rightBRAF/MEK-targeted therapy for BRAF-mutant melanoma
- arrow_rightSystemic immunotherapy and targeted therapy sequencing
- arrow_rightImaging surveillance and response assessment
- arrow_rightMultidisciplinary care with dermatology, surgery, and radiation oncology
- arrow_rightMelanoma staging and treatment planning
- arrow_rightCoordination across surgical and systemic oncology teams
Cancer Immunotherapy & Checkpoint Blockade
Pioneer-level expertise in immune checkpoint inhibitor therapy and novel immunotherapy combinations across solid tumours.
- arrow_rightIpilimumab therapy for eligible melanoma patients
- arrow_rightImmune-related adverse event assessment and management
- arrow_rightNivolumab and nivolumab-plus-ipilimumab combination therapy
- arrow_rightBiomarker-guided patient selection for checkpoint inhibitors
- arrow_rightDual checkpoint blockade protocols in advanced melanoma
- arrow_rightRational immunotherapy combinations in clinical trial settings
Translational Research & Clinical Trials
Pioneering laboratory and early-phase clinical trial research across tumour immunology, cancer vaccines, and immune resistance mechanisms.
- arrow_rightTumour microenvironment biology and immune resistance
- arrow_rightBiomarkers of immunotherapy response and resistance
- arrow_rightT-cell exhaustion and immune modulation strategies
- arrow_rightCancer Vaccine Collaborative leadership with nearly 50 early-phase trials
- arrow_rightPersonalised and antigen-specific vaccine strategies
Procedures & Treatment Approaches
Systemic oncology and multidisciplinary melanoma care
Dr. Wolchok provides evidence-based systemic treatment for melanoma patients, including immunotherapy, targeted therapy, and chemotherapy when clinically appropriate, alongside clinical trial evaluation and multidisciplinary care coordination.
Melanoma Immunotherapy
Medical OncologyCheckpoint inhibitor-based systemic therapy for advanced and metastatic melanoma.
Targeted Therapy for Melanoma
Targeted TherapyMolecularly guided systemic therapy for patients with BRAF-mutant and other targetable melanoma subtypes.
Multidisciplinary Melanoma Care
MultidisciplinaryCoordinated care across surgical oncology, dermatology, radiation oncology, and medical oncology.
Clinical Trial Evaluation
Complex DiseaseAssessment of clinical trial eligibility and enrolment for patients with advanced melanoma or other solid tumours.
Second Opinion Consultation
Second OpinionExpert independent review of melanoma diagnosis, staging, and treatment planning.
Research & Publications
Landmark contributions to melanoma immunotherapy and translational cancer research
Dr. Wolchok is among the most cited oncology researchers in the world, with over 248,000 citations. His work has shaped the clinical landscape of melanoma treatment and cancer immunotherapy.
A full publication list is available on Dr. Wolchok's Weill Cornell Medicine faculty page and Google Scholar profile. CancerFax can help coordinate access to clinical trial opportunities at the Meyer Cancer Center.
Education & Training
Dr. Wolchok trained at Princeton University and New York University, earning his BA, MS, PhD, and MD before completing residency at NYU School of Medicine and fellowship at Memorial Sloan Kettering Cancer Center.
Clinical Experience
Dr. Wolchok spent over two decades at Memorial Sloan Kettering Cancer Center, rising to lead its Melanoma and Immunotherapeutics Service, before joining Weill Cornell Medicine in 2022 as Meyer Cancer Center Director.
Languages & International
Dr. Wolchok consults in the following language.
CancerFax can coordinate professional medical interpreter support for international patients requiring consultations in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Wolchok.
How CancerFax Helps You Access Dr. Jedd Wolchok
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jedd Wolchok's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Jedd Wolchok's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jedd Wolchok before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jedd Wolchok's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jedd Wolchok's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jedd Wolchok's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Jedd Wolchok
Dr. Wolchok specialises primarily in melanoma, including advanced and metastatic melanoma. His clinical practice covers systemic treatment with immunotherapy, targeted therapy, and chemotherapy, as well as imaging surveillance and multidisciplinary care coordination. His laboratory research spans multiple solid tumour types through the lens of cancer immunotherapy.
Dr. Wolchok practises at Weill Cornell Medicine and NewYork-Presbyterian / Weill Cornell Medical Center in New York City, United States. He is the Meyer Director of the Sandra and Edward Meyer Cancer Center and also leads the Parker Institute for Cancer Immunotherapy Center at Weill Cornell Medicine.
Dr. Wolchok practises at Weill Cornell Medicine / NewYork-Presbyterian in New York. CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Wolchok, subject to hospital availability and case acceptance. International patients should confirm appointment pathways, virtual consultation availability, and insurance requirements directly with the hospital or through CancerFax.
Submit your medical reports, imaging, pathology findings, and treatment history through CancerFax using the Send Your Reports option. The CancerFax team will review your case, prepare the documentation for submission, and coordinate the next steps with Weill Cornell Medicine, subject to the doctor's availability and case acceptance. Second-opinion requests for melanoma and immunotherapy-related cases are a particular area of expertise.
Dr. Wolchok is internationally recognised for his role in the clinical development of ipilimumab (CTLA-4 checkpoint inhibitor) and the nivolumab-plus-ipilimumab combination for advanced melanoma β both of which are now standard treatments. He also offers BRAF/MEK-targeted therapy for BRAF-mutant melanoma and is an active clinical investigator in novel immunotherapy trials.
Yes. Dr. Wolchok has a long history of clinical trial leadership, including pivotal roles in ipilimumab and CheckMate 067 trials. He currently leads an NIH R01-funded research programme and directs the Parker Institute for Cancer Immunotherapy Center at Weill Cornell Medicine, which conducts early-phase and translational immunotherapy trials. Eligible patients may be assessed for trial participation through CancerFax-coordinated case review.
Connect with Jedd Wolchok Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.